USANA Health Sciences (USNA) Is Down 25.4% After Surprising Q3 Loss and Compensation Plan Impact – Has The Bull Case Changed?

• USANA Health Sciences recently announced preliminary third-quarter results, revealing a sharper-than-expected decline in profitability and forecasting a net loss of US$6.5 million due to weaker sales and underperformance in its direct-to-consumer business, Hiya.
• This setback highlights significant challenges with the company's new compensation plan, which led to a more pronounced slowdown in sales productivity than initially anticipated.
• We’ll examine how the unexpected impact of the new compensation plan could shape USANA Health Sciences' investment narrative moving forward.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

USANA Health Sciences Investment Narrative Recap

To be a shareholder in USANA Health Sciences right now, you need to believe in the company’s ability to execute a turnaround as it modernizes its direct sales model and enhances digital tools to reignite distributor engagement. The recent preliminary results, with a larger-than-expected net loss and underperformance in its direct-to-consumer business, directly affect the short-term outlook; the most important near-term catalyst, recovery of sales productivity under the new compensation plan, is now the single biggest risk to the business as it struggles to stabilize active customer and brand partner growth. Among recent announcements, USANA's new line of updated and advanced nutritionals announced in September 2025 stands out. Product innovation is intended to address rising health-consciousness and shifting consumer preferences, but the latest sales shortfalls indicate these initiatives will be under pressure until distributor momentum and customer acquisition are back on track. In contrast, investors should be aware that ongoing weakness in sales productivity has...

Read the full narrative on USANA Health Sciences (it's free!)

USANA Health Sciences' outlook points to $1.1 billion in revenue and $76.0 million in earnings by 2028. This implies annual revenue growth of 8.4% and an increase in earnings of $41.9 million from the current $34.1 million.

Uncover how USANA Health Sciences' forecasts yield a $39.00 fair value, a 92% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community fair value estimates for USANA range from US$39 to US$64.28 per share across two perspectives. While new digital tools and compensation updates were meant to fuel a turnaround, the latest results show how dependent the company’s near-term recovery remains on distributor engagement, see how other investors are interpreting this risk.

Explore 2 other fair value estimates on USANA Health Sciences - why the stock might be worth just $39.00!

Build Your Own USANA Health Sciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your USANA Health Sciences research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free USANA Health Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate USANA Health Sciences' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com